John McDonald

Corporate VP, Global R&D Business Development at Novo Nordisk

John McDonald joined Novo Nordisk in October 2018. Prior to Novo Nordisk, John held various senior roles at Biogen, Inc., MPM Capital, Genzyme Corporation, Millennium Pharmaceuticals, and Genentech.

In his career, John was a Co-Founder of Solasia Pharma KK, a public oncology-focused company traded on Tokyo's Mothers Stock Exchange, and has led or participated in the evaluation, structuring and negotiating of numerous mergers and acquisitions, licenses and strategic alliances, e.g., Biogen’s recent collaborations with Ionis Pharmaceuticals (including the April 2018, $1 Billion upfront drug discovery relationship), Mitsubishi Tanabe, AGTC, Sangamo BioSciences, Portola Pharmaceuticals, Inc., partnering Biogen's marketed products with UCB in China, Biogen’s acquisition of Stromedix, Inc., Millennium's Ex-U.S. collaboration with Ortho Biotech/Johnson & Johnson for VELCADE, the restructuring of Millennium's relationship with Schering-Plough Corp. for INTEGRILIN, the sale of Millennium's interest in its CAMPATH joint venture, Genzyme’s alliance with BioMarin for ALDURAZYME, and Genentech’s alliances with Xoma Corporation (RAPTIVA) and IDEC Pharmaceuticals (RITUXAN).